Solventum Co. (NYSE:SOLV) Stock Holdings Trimmed by Johnson Investment Counsel Inc.

Johnson Investment Counsel Inc. reduced its position in Solventum Co. (NYSE:SOLV) by 9.1% in the 4th quarter, Holdings Channel reports. The institutional investor owned 12,707 shares of the company’s stock after selling 1,271 shares during the period. Johnson Investment Counsel Inc.’s holdings in Solventum were worth $839,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SOLV. Trian Fund Management L.P. grew its holdings in shares of Solventum by 32.9% during the third quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock valued at $496,842,000 after purchasing an additional 1,765,676 shares during the last quarter. State Street Corp grew its holdings in shares of Solventum by 3.1% during the third quarter. State Street Corp now owns 6,107,550 shares of the company’s stock valued at $425,818,000 after purchasing an additional 185,938 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Solventum by 4.0% during the third quarter. Geode Capital Management LLC now owns 3,347,719 shares of the company’s stock valued at $232,608,000 after purchasing an additional 128,317 shares during the last quarter. Hotchkis & Wiley Capital Management LLC bought a new position in shares of Solventum during the third quarter valued at approximately $125,488,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Solventum by 0.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,053,771 shares of the company’s stock valued at $73,469,000 after purchasing an additional 3,745 shares during the last quarter.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. The Goldman Sachs Group upped their target price on Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a report on Monday, March 3rd. Bank of America upped their target price on Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a report on Wednesday, February 26th. Piper Sandler increased their price objective on Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a report on Friday, February 28th. Wells Fargo & Company increased their price objective on Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a report on Friday, February 28th. Finally, Mizuho increased their price objective on Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a report on Monday, March 3rd. One analyst has rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $79.86.

Solventum Stock Performance

SOLV opened at $73.95 on Thursday. The company has a market capitalization of $12.79 billion and a price-to-earnings ratio of 26.89. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $85.92. The business has a 50 day moving average price of $74.24 and a two-hundred day moving average price of $70.96.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.